Get the Stockscreener App
15.08
8.77%
-1.45
After Hours:
15.00
-0.08
-0.53%
Alto Neuroscience Inc stock is traded at $15.08, with a volume of 419.02K.
It is down -8.77% in the last 24 hours and up +12.29% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$16.53
Open:
$16.56
24h Volume:
419.02K
Relative Volume:
0.25
Market Cap:
$468.48M
Revenue:
-
Net Income/Loss:
$-49.81M
P/E Ratio:
-6.9944
EPS:
-2.156
Net Cash Flow:
$-42.93M
1W Performance:
-15.94%
1M Performance:
+12.29%
6M Performance:
+541.70%
1Y Performance:
+247.47%
1-Day Range:
$14.08
$16.56
1-Week Range:
$14.08
$18.31
52-Week Range:
$1.60
$20.91
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
15.08 | 513.53M | 0 | -49.81M | -42.93M | -2.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
Is Alto Neuroscience Inc. stock supported by strong fundamentals2026 world cup usa national team qualification young talents high defensive line group prediction guide - Улправда
Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating - Investing.com Canada
Chardan Capital Doubles Price Target for ANRO to $30 and Maintai - GuruFocus
Chardan Capital Raises Alto Neuroscience (NYSE:ANRO) Price Target to $30.00 - MarketBeat
Alto Neuroscience (NYSE:ANRO) Shares Down 6%What's Next? - MarketBeat
Does Alto Neuroscience Inc. stock trade at a discount to peersHead and Shoulders Patterns & Superior Portfolio Growth - bollywoodhelpline.com
Alto Neuroscience, Inc.'s (NYSE:ANRO) Institutional Investors Lost 10% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6%Here's Why - MarketBeat
Alto Neuroscience, Inc. (NYSE:ANRO) is definitely on the radar of institutional investors who own 33% of the company - Yahoo Finance
Alto Neuroscience Stock 9-Day Winning Spree: Stock Climbs 51% - Trefis
Will Alto Neuroscience Inc. stock continue upward momentumJuly 2025 Outlook & Fast Moving Stock Trade Plans - Улправда
Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Volume Summary: What sentiment indicators say about Alto Neuroscience Inc stockJuly 2025 Update & Accurate Trade Setup Notifications - moha.gov.vn
Is Alto Neuroscience Inc. stock safe for conservative investors2025 Institutional Moves & AI Forecast for Swing Trade Picks - Улправда
Market Review: Does Alto Neuroscience Inc. stock trade at a discount to peersJuly 2025 Momentum & Low Drawdown Investment Ideas - Улправда
Alto Neuroscience Stock Rockets 51% With 8-Day Winning Streak - Trefis
What margin trends mean for Alto Neuroscience Inc. stock2025 Price Action Summary & Safe Capital Investment Plans - Улправда
How Alto Neuroscience Inc. stock benefits from global expansion2025 Biggest Moves & Verified Momentum Stock Watchlist - DonanımHaber
Will Alto Neuroscience Inc. stock sustain uptrend momentum2025 Winners & Losers & Daily Stock Trend Watchlist - DonanımHaber
Why Alto Neuroscience Inc. stock could be next big winnerTrend Reversal & Verified Momentum Stock Watchlist - DonanımHaber
Stock Analysis: Is Alto Neuroscience Inc. stock a good choice for value investors2025 Price Targets & Daily Volume Surge Trade Alerts - Улправда
Why Alto Neuroscience Inc. stock remains undervaluedJuly 2025 Volume & Consistent Profit Alerts - Улправда
Is Alto Neuroscience Inc. stock a good choice for value investorsStop Loss & Weekly High Return Stock Forecasts - Улправда
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025ANRO - TMX Newsfile
Alto Neuroscience (NYSE:ANRO) Stock Price Up 7.1%Here's Why - MarketBeat
Alto Neuroscience (NYSE:ANRO) Shares Gap DownWhat's Next? - MarketBeat
Alto Neuroscience (NYSE:ANRO) Sets New 12-Month HighShould You Buy? - MarketBeat
Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc. - MarketBeat
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock - MSN
Market Trends: Is Alto Neuroscience Inc stock recession proofDay Trade & Verified Swing Trading Watchlist - moha.gov.vn
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Can Alto Neuroscience Inc. stock maintain growth trajectoryWeekly Loss Report & Technical Analysis for Trade Confirmation - Newser
Will Alto Neuroscience Inc. stock announce special dividendWeekly Trade Summary & Verified Momentum Watchlists - Newser
Aug Wrap: Is Alto Neuroscience Inc. stock supported by strong fundamentalsJuly 2025 News Drivers & Precise Swing Trade Alerts - BỘ NỘI VỤ
What insider purchases suggest about Alto Neuroscience Inc. stockQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - Newser
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08December 3, 2025 - BioSpace
Is Alto Neuroscience Inc. stock undervalued after correctionTrade Volume Summary & Long-Term Growth Plans - Newser
Can Alto Neuroscience Inc. stock double in next 5 yearsMarket Activity Report & Safe Investment Capital Preservation Plans - Newser
What technical patterns form on Alto Neuroscience Inc. stock chartsPortfolio Performance Summary & Step-by-Step Swing Trade Plans - Newser
Is Alto Neuroscience Inc. stock safe for risk averse investorsQuarterly Profit Report & AI Driven Price Forecasts - Newser
What dividend safety rating applies to Alto Neuroscience Inc. stockJuly 2025 PreEarnings & Real-Time Buy Zone Alerts - Newser
What sentiment indicators say about Alto Neuroscience Inc. stock - Newser
Alto Neuroscience (ANRO) Stock Analysis Report | Financials & Insights - Benzinga
Short Covering: Why Alto Neuroscience Inc. stock remains undervaluedJuly 2025 Action & Advanced Technical Signal Analysis - moha.gov.vn
Can Alto Neuroscience Inc. stock test all time highsLayoff News & Risk Controlled Stock Pick Alerts - Newser
Is Alto Neuroscience Inc. stock a buy during volatile markets2025 Key Lessons & Expert Approved Momentum Trade Ideas - Newser
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):